Prof Daria Mochly-Rosen, Stanford University, USA
Daria Mochly-Rosen is a Professor of Chemical and Systems Biology and the George D. Smith Professor for Translational Medicine at Stanford University School of Medicine. She leads a multi-disciplinary research lab that includes chemists, biochemists, biologists and physician scientists and has used her basic research discoveries to develop a number of drug leads for human diseases with a particular interest in mitochondrial biology and pathology. Dr Mochly-Rosen served on many university leadership committees, was chair of her department (2001-2004) and the Senior Associate Dean for Research, Stanford University School of Medicine (between 2006 and 2013). She has published over 240 papers and over 30 patents and patent applications and has founded three companies: KAI Pharmaceuticals (2003-2011), ALDEA (now Aviv Therapeutics; 2013-) and Mitoconix (2016-).
Dr John Thompson, National Poisons Information Service, UK
Dr John Thompson is Director of the National Poisons Information Service (Cardiff), one of four units responsible for delivering advice on the management of poisoned patients within the United Kingdom and which also provides services internationally. He is the national lead for the United Kingdom Poisons Information Database (UKPID) and was previously Head of the Chemical Incident Management Support Unit, advising on the management of chemical incidents and is a consultant to the World Health Organisation Collaborating Centre for the Public Health Management of Chemical Exposures. Dr Thompson is Senior Lecturer in Clinical Pharmacology at Cardiff University. Clinically, in addition to providing general internal medicine services, Dr Thompson is the lead consultant for a specialised eight-bedded poisons treatment unit and delivers specialty clinics in toxicology, hypertension and adverse drug reactions.
Prof Andrew McLachlan, The University of Sydney School of Pharmacy, AUS
Professor Andrew McLachlan is a pharmacist, academic and researcher with experience in clinical pharmacology and the quality use of medicines. He is Head of School and Dean at The University of Sydney School of Pharmacy. Andrew is the Program Director of a NHMRC Centre for Research Excellence in Medicines and Ageing. He has served as the chair of a human research ethics committee and serves on Australian government committees related to medicines policy, evaluation, regulation and antidoping. He became a Member of the Order of Australia for his significant service to pharmacy as a researcher, educator and administrator, and to professional medical and scientific organisations.